In 2008, ACTIVE BIOTECH filed Oppositions against two JENOMIC patents with claims covering ACTIVE BIOTECH's key cancer drug ANYARA. In hearings held at
the Hague in 2008, the Opposition Panel rejected ACTIVE BIOTECH's bid to revoke the patents. The Board upheld JENOMIC's key patent claims covering ANYARA both struturally and
functionally. Dissatisfied with the verdict ACTIVE BIOTECH appealed but withdrew its appeal voluntarily in 2012. Both JENOMIC patents were issued in the EPO with claims covering
ANYARA. The minutes and verdict of the Opposition proceedings are provided below.
Active Defeated in Two 2008 European Opp[...]
Adobe Acrobat document [867.5 KB]
About Jenomic Research Institute
Jenomic is a biotech company devoted to developing novel drugs and drug vehicles for treatment of cancer. These efforts are supported by a raft of peer- reviewed publications and worldwide patents/patent applications.
The research team is led by David S. Terman, MD, an emeritus member of the American Society of Clinical Investigation (academia's physician-scientist honor society), former Professor of Medicine, Microbiology and Immunology and Founding Director of Cancer Biology Program at Baylor College of Medicine. He is currently Adjunct Professor of Biochemistry and Molecular Biology at UAB in Birmingham. Dr. Terman is cited in Who's Who in America 2008-2013